Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 16/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785695 | 0.86 | MTNR1A (0.43) | MTNR1AMEN1CYP1A2KMT2A | |
| SCHEMBL533912 | 0.79 | MTNR1A (0.52) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL8003452 | 0.78 | IAPP (0.40) | MTNR1AMEN1LMNACYP1A2TSHR | |
| SCHEMBL29686650 | 0.77 | MTNR1A (0.61) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL533866 | 0.77 | MTNR1A (0.61) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL27620072 | 0.75 | L3MBTL1 (0.44) | MTNR1ALMNACYP1A2TSHR | |
| SCHEMBL533955 | 0.75 | MTNR1A (0.51) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL27450481 | 0.74 | MTNR1A (1.00) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL19460839 | 0.73 | KDM4E (0.46) | LMNACYP1A2 | |
| SCHEMBL31627779 | 0.73 | MTNR1A (0.53) | MTNR1AMTNR1BMEN1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | MTNR1A 2293/4885MTNR1B 1285/4885MEN1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.